scholarly journals Intraoperative radiation therapy in non-breast cancer patients: A report of 26 cases from Shiraz, south of Iran

2020 ◽  
Author(s):  
Majid Akrami ◽  
Hamid Nasrollahi ◽  
Mostafa Vahabi ◽  
Seyed Hassan Hamedi ◽  
Sedigheh Tahmasebi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Intraoperative Radiation Therapy ◽  
Breast Cancer Patients ◽  
Intraoperative Radiation

scholarly journals Changes in peripheral immune cells after intraoperative radiation therapy in low-risk breast cancer

2020 ◽  
Vol 62 (1) ◽  
pp. 110-118
Author(s):  
Isabel Linares-Galiana ◽  
Miguel Angel Berenguer-Frances ◽  
Rut Cañas-Cortés ◽  
Monica Pujol-Canadell ◽  
Silvia Comas-Antón ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Single Dose ◽  
Cancer Patients ◽  
Antitumor Immunity ◽  
Low Risk ◽  
Intraoperative Radiation Therapy ◽  
Breast Cancer Patients ◽  
Intraoperative Radiation ◽  
Risk Breast Cancer

Abstract A detailed understanding of the interactions and the best dose-fractionation scheme of radiation to maximize antitumor immunity have not been fully established. In this study, the effect on the host immune system of a single dose of 20 Gy through intraoperative radiation therapy (IORT) on the surgical bed in low-risk breast cancer patients undergoing conserving breast cancer has been assessed. Peripheral blood samples from 13 patients were collected preoperatively and at 48 h and 3 and 10 weeks after the administration of radiation. We performed a flow cytometry analysis for lymphocyte subpopulations, natural killer cells (NK), regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSCs). We observed that the subpopulation of NK CD56+high CD16+ increased significantly at 3 weeks after IORT (0.30–0.42%, P < 0.001), while no changes were found in immunosuppressive profile, CD4+CD25+Foxp3+Helios+ Treg cells, granulocytic MDSCs (G-MDSCs) and monocytic MDSCs (Mo-MDSCs). A single dose of IORT may be an effective approach to improve antitumor immunity based on the increase in NK cells and the non-stimulation of immunosuppressive cells involved in immune escape. These findings support future combinations of IORT with immunotherapy, if they are confirmed in a large cohort of breast cancer patients.

Acute and Chronic Complications in Breast Cancer Patients Treated with Intraoperative Radiation Therapy

2016 ◽  
Vol 23 (10) ◽  
pp. 3304-3309 ◽  
Author(s):  
Melinda Epstein ◽  
Melvin Silverstein ◽  
Kevin Lin ◽  
Brian Kim ◽  
Sadia Khan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Intraoperative Radiation Therapy ◽  
Breast Cancer Patients ◽  
Chronic Complications ◽  
Intraoperative Radiation

scholarly journals Intraoperative radiation therapy for breast cancer patients: current perspectives

2017 ◽  
Vol Volume 9 ◽  
pp. 257-263 ◽  
Author(s):  
Sunil Dutta ◽  
Shayna Showalter ◽  
Timothy Showalter ◽  
Bruce Libby ◽  
Daniel Trifiletti
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Intraoperative Radiation Therapy ◽  
Breast Cancer Patients ◽  
Intraoperative Radiation

Skin dose assessment with treatment planning system (TPS) and skin reaction evaluation of early breast cancer patients treated via an intraoperative radiation therapy (IORT) device

2018 ◽  
Vol 17 (4) ◽  
pp. 417-421
Author(s):  
Omid Baziar ◽  
Hamid Gholamhosseinian ◽  
Mohammad Naser Forghani
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Planning System ◽  
Treatment Planning System ◽  
Intraoperative Radiation Therapy ◽  
Skin Dose ◽  
Breast Cancer Patients ◽  
Skin Reactions ◽  
Intraoperative Radiation ◽  
Skin Doses

AbstractPurposeTo assess skin dose and incidence of skin reactions in early breast cancer patients treated via Intrabeam™ intraoperative radiation therapy (IORT) device.Materials and methodsIn total, 250 breast cancer patients treated with a single fraction of 20 Gy using 50 kV photon were recruited. The applicator to skin distance (ASD) was measured before the initiation of the radiation and the skin dose in each patient was accordingly calculated based on the treatment planning system (TPS).ResultsThe average skin doses calculated were equal to 7·91, 5·83, 3·96 and 2·14 Gy for 6–10, 10–15, 15–20 and 20–30 mm ASD values, respectively. It is noticeable that the skin doses could be lower than the TPS measurements up to 45%, mostly due to lack of backscatter radiation in breast tissue compared with the full scatter condition in the Zeiss water phantom. Finally, only three patients showed low-grade skin reactions 1 week after IORT. A review of the related literature also revealed the incidence of lower skin complications among patients treated via Intrabeam™ compared with MammoSite™ machine.ConclusionsThe Intrabeam™ TPS did not seem to be very reliable for accurate skin dosimetry. However, breast cancer treatment using Intrabeam™ could result in fewer incidences of skin reactions than MammoSite™ machine.

Sign in / Sign up

Export Citation Format

Share Document